Blog

Home  /  Collaborations   /  PTJA11 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

PTJA11 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

PTJA11 addresses ‘cefiderocol the for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’, submitted by Shionogi BV. We are delighted that AIFA and NOMA are authoring this assessment.

We will be issuing an Open Call for Patient Input in due course.